PAST
Adenocarcinoma of the anus is a rare subtype of anal cancer and is thought to represent between 5 and 10% of all anal cancer cases. 1 Previous studies have reported that anal adenocarcinoma (AA) carries a worse prognosis when compared with anal squamous cell carcinoma (AS). 1, 2 However, due to the rarity of this disease, there are currently no evidence-based treatment guidelines. AS is treated with definitive chemoradiation (CRT). In contrast, AA has typically been treated similarly to a low-lying rectal adenocarcinoma, i.e. trimodality therapy with neoadjuvant CRT followed by abdominoperineal resection (APR). Unfortunately, the data on this treatment strategy are limited to retrospective institutional reviews.
PRESENT
The National Cancer Data Base (NCDB) was queried (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) for patients with AA, 3 and was used to collect a large amount of patients to adequately determine the role of trimodality treatment versus CRT alone for this patient population. Data on AS patients were also collected to serve as a comparison population. Median overall survival (OS) was 72.5 and 143.8 months (p \ 0.001) for AA and AS patients, respectively. Survival was higher for AA patients undergoing APR within 6 months of CRT (88.3 vs. 58.1 months, p \ 0.001) compared with AA patients who had an APR 6 months after CRT. On multivariable analysis, factors associated with worse survival included adenocarcinoma subtype, age C 55 years, male sex, T stage C 3, comorbidity score C 1, lower income, and treatment at a non-academic institution.
FUTURE
Based on our results, 3 trimodality treatment is associated with improved OS for these patients. Due to the rarity of this histology, prospective clinical trials are unlikely to accrue enough patients to confirm this benefit. As a result, given the large numbers of patients included, this data may serve as the best resource for providers encountering this rare disease type.
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